Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.
The pharmacy benefits manager (PBM) Prime Therapeutics, owned by 18 Blue Cross Blue Shield plans or subsidiaries, announced it will pay for the therapy empagliflozin (Jardiance) under an outcomes-based contract with Boehringer-Ingelheim. The companies announced the deal in a statement.
Empagliflozin, first approved to treat type 2 diabetes (T2D), was the first such therapy found to have cardiovascular (CV) benefits and the first to have an FDA indication to reduce CV mortality. Since then, a competitor in the same class of sodium glucose co-transporter-2 (SGLT2) inhibitors, canagliflozin (Invokana) by Janssen, was also found to have CV benefits; the drug sponsor is also seeking a CV indication from FDA.
Competition between the 2 drugs is fierce. Going into 2018, CVS Caremark removed empagliflozin in favor of canagliflozin, following the announcement of the latter drug's CV results in June 2017.
Two other SGLT2 inhibitors also have FDA approval: dapagliflozin (Farxiga) from AstraZeneca; and ertugliflozin (Steglatro) from Merck and Pfizer, which was approved along with combinations at the end of 2017.
“Because diabetes affects nearly 10% of the US population, Prime actively works to find solutions that can improve our members’ health outcome and control the overall costs of diabetes,” said Jonathan Gavras, MD, chief medical officer at Prime. He said the agreement would allow for the collection of key data beyond pharmacy claims and insights gained would “help drive the greatest value from the treatment.”
Alec Mahmood, chief financial officer at Prime, said the contract was one of several in recent months that sought to align incentives among payers, manufacturers, providers, and health plan members to make sure “drugs work as they are intended.”
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen